What ‘Modicare’ May Mean (Or Not) For Pharma In India
Ambitious and complex to say the least, India’s “Modicare” – the proposed National Health Protection Scheme – could have significant implications on market expansion in the country. Scrip brings you an early take from pharma industry experts on what to expect (or not) and where the key challenges lie.
You may also be interested in...
Paul Hudson, CEO, Novartis Pharmaceuticals, was recently in India along with the executive leadership team of the Swiss multinational. In a wide-ranging exclusive interview with Scrip, he discussed Cosentyx’s edge over its competition, Entresto’s “incredibly bright future”, including in emerging markets like India, and why transparency on the scale of rebates in the US is "overdue."
Lara Bezerra, Roche’s new managing director in India, outlines in an interview with Scrip how the Swiss multinational is now looking at the Indian market through a different lens and beyond short-term gains.
2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.